Recipients and results, side by side
Blood availability, scanned fat area and body weight measure different things. The recipients and the units give each result its meaning.
Study settings
| Compound and study | Recipients | Measurement |
|---|---|---|
| BPC-157 pharmacokinetics | Rats and beagle dogs | Availability after administration into muscle: roughly 14–19% in rats and 45–51% in dogs. |
| BPC-157 safety pilot | Two healthy adults | No observed adverse events or measurable safety-biomarker changes; no untreated comparator. |
| Tesamorelin abdominal-fat trial | 50 adults receiving HIV treatment | Visceral fat area: treatment effect −42 cm² against placebo over six months. |
| Semaglutide STEP 1 | 1,961 adults with overweight or obesity, without diabetes | Mean weight change −14.9% against −2.4% on placebo at 68 weeks. |
| Tirzepatide versus semaglutide, SURMOUNT-5 | 751 adults with obesity, without type 2 diabetes | Mean weight change −20.2% against −13.7% at 72 weeks. |
The change of unit gives these rows their interest for me. Availability in blood, abdominal fat area and body weight answer different questions, even when every result concerns a peptide. These rows provide no common scale for ranking the compounds.
Comparisons within and between trials
The direct obesity comparison assigned participants to tirzepatide or semaglutide within one experiment. That supports a comparison between its treatment groups. Placing the STEP 1 semaglutide result next to the SURMOUNT-1 tirzepatide result crosses into separate trials, with different participants and protocols.
The numerical difference between those separate studies would be easy to calculate and easy to overinterpret. I prefer the direct result when the question matches the trial. Neither obesity comparison substitutes for tesamorelin research in HIV-associated lipodystrophy or for a controlled human trial of BPC-157 injury repair.
FDA status
Semaglutide has approved uses for type 2 diabetes, chronic weight management, cardiovascular risk reduction in adults with established cardiovascular disease and excess weight, and MASH since 2025. Tirzepatide has approvals for type 2 diabetes, chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity.
Tesamorelin’s FDA approval is limited to reducing excess abdominal fat in adults with HIV-associated lipodystrophy. BPC-157 has no approved human treatment use anywhere and remains listed as ineligible for pharmacy compounding pending further evaluation. Off-label prescribing, research availability and a pending regulatory review each leave the approved indication unchanged.
An active ingredient is a useful chemical description. A medical conclusion requires more of me: checking the formulation, recipient, measured outcome and safety account. The compound articles give those details room to breathe.